Approximately 300 tablets of Losartan Potassium (100 mg), a blood pressure medication, are being recalled because trace amounts of an impurity called N-Nitroso N-Methyl 4-amino butyric acid (NMBA) were found in the active ingredient. The affected products are white to off-white, tear-drop shaped tablets debossed with "H" on one side and "145" on the other, sold in 30-count bottles. These tablets were distributed to a physician's office in California.
The recall is due to the presence of NMBA, which is classified as a potential human carcinogen. While no injuries have been reported, long-term exposure to this impurity above acceptable levels may increase the risk of cancer.
Healthcare provider consultation and pharmacy refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.